Glucagon receptor antagonists
AssigneeLigand Pharmaceuticals Incorporated
InventorsLin Zhi, Ian Henderson, Joseph Kaloko, Martin Osterhout
Life of this patent
Estimating the term…
Abstract
Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.
Claims20
A crystalline form of sodium (R)-2-(4-(2-(4′-(tert-butyl)-[1,l′-biphenyl]-4-yl)-3-oxo-3-((2′,4′,6′-trimethyl-[1,1′-biphenyl]-4-yl)amino) propyl)benzamido) ethane-1-sulfonate characterized as Form A,
- wherein Form A is characterized by three or more peaks in an X-ray powder diffraction pattern, wherein the three or more peaks are selected from the group consisting of a peak at 4.7±0.2 degrees, a peak at 7.0±0.2 degrees, a peak at 9.3 degrees, a peak at 11.0±0.2 degrees, a peak at 11.4±0.2 degrees, a peak at ±0.2 11.9 degrees, a peak at 13.8±0.2 degrees, a peak at 21.4±0.2 degrees, and a peak at 23.8±0.2 degrees, when measured at room temperature with monochromatic Kα1 radiation.
Dependencies are inferred from the claim text.